<p>InflaRx（纳斯达克代码：IFRX - 获取免费报告）于周一发布了季度财报。公司报告本季度每股收益为（$0.16），符合分析师一致预期的（$0.16），据 Zacks 报道。公司本季度的收入为 30,000 美元，而分析师预期为 30,000 美元。</p>
<h2>InflaRx 价格表现</h2>
<p>周三午盘交易中，IFRX 股价上涨 0.03 美元，达到 1.68 美元。该公司的股票交易量为 2,327,579 股，而其平均交易量为 1,075,154 股。InflaRx 的 52 周低点为 0.71 美元，52 周高点为 2.82 美元。该公司的 50 日移动平均价格为 1.38 美元，200 日移动平均价格为 1.18 美元。该股票的市值为 1.1278 亿美元，市盈率为-2.18，贝塔值为 1.38。</p>
<h2>InflaRx 的机构交易</h2>
<p>机构投资者最近对该股票的持仓进行了调整。Woodline Partners LP 在第一季度收购了 InflaRx 的新股份，价值约为 766,000 美元。Adage Capital Partners GP L.L.C.在第二季度购买了 InflaRx 的新头寸，价值为 262,000 美元。最后，Cubist Systematic Strategies LLC 在第一季度将其在 InflaRx 的持仓增加了 33.9%。Cubist Systematic Strategies LLC 目前拥有 30,053 股该公司的股票，价值 31,000 美元，此前在上个季度又购买了 7,616 股。目前，42.39% 的股票由机构投资者和对冲基金持有。</p>
<h2>分析师设定新目标价</h2>
<p>一些股票研究分析师最近对该股票发表了看法。HC Wainwright 在 9 月 2 日的报告中对 InflaRx 的股票进行了覆盖，给予 “买入” 评级，并设定目标价为 6.00 美元。Weiss Ratings 在 11 月 5 日的报告中重新发布了对 InflaRx 的 “卖出（d-）” 评级。华尔街 Zen 在周六的研究报告中将 InflaRx 的评级从 “持有” 下调至 “卖出”。Guggenheim 在周一的报告中将 InflaRx 的目标价从 10.00 美元上调至 22.00 美元，并给予该股票 “买入” 评级。最后，Raymond James Financial 在周二的研究报告中重新发布了对 InflaRx 的 “跑赢大盘” 评级。五位研究分析师对该股票给予了 “买入” 评级，一位分析师给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，平均目标价为 8.60 美元。</p>
<p><strong>查看我们对 IFRX 的最新股票分析</strong></p>
<h2>InflaRx 公司简介</h2>
<p>（获取免费报告）</p>
<p>InflaRx N.V.是一家临床阶段的生物制药公司，在德国和美国发现并开发使用 C5a 技术的抑制剂。该公司的 C5a 是一种炎症介质，参与多种自身免疫和其他炎症性疾病的进展。其主要产品候选药物是 vilobelimab，一种新型的静脉注射首创抗 C5a 单克隆抗体，已完成针对 hidradenitis suppurativa（一种罕见且慢性的致残性全身性炎症皮肤病）的第三阶段临床试验；针对抗中性粒细胞细胞质抗体相关性血管炎（一种罕见且危及生命的自身免疫疾病）的第二阶段临床试验；治疗脓皮病（pyoderma gangraenosum，一种慢性炎症性皮肤疾病）的第二阶段探索性研究；以及治疗对 PD-1/PD-L1 抑制剂耐药/难治的局部晚期或转移性鳞状细胞癌的第二阶段临床开发。</p>
<h2>特色文章</h2>
<ul>
<li>我们更看好的五只股票而非 InflaRx</li>
<li>风险承受能力，适合所有人的方案并不存在</li>
<li>Rocket Lab 股票在财报后上涨，尽管 Neutron 延迟</li>
<li>如何使用股票筛选器寻找股票</li>
<li>2025 年第四季度，西方石油是一个买入机会</li>
<li>最佳能源股票 - 现在值得购买的能源股票</li>
<li>3 只被打压的股票在本财报季有反弹潜力</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUZSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUZSWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 InflaRx 吗？</h2>
<p>在考虑 InflaRx 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 InflaRx 并不在名单上。</p>
<p>虽然 InflaRx 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

IFRX

<p>InflaRx（纳斯达克代码：IFRX）公布了其季度财报，报告每股收益（EPS）为（$0.16），符合分析师的预期。该公司还报告收入为 30,000 美元，与预测一致。股票交易价格为 1.68 美元，市值为 1.1278 亿美元。分析师的评级不一，普遍共识为 “适度买入”，平均目标价为 8.60 美元。InflaRx 是一家临床阶段的生物制药公司，专注于用于炎症疾病的 C5a 技术</p>

<p>InflaRx (NASDAQ:IFRX - Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.16) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.16), Zacks reports. The company had revenue of $0.03 million during the quarter, compared to analysts' expectations of $0.03 million.</p>
<div class="lb-trans"><p>InflaRx（纳斯达克代码：IFRX - 获取免费报告）于周一发布了季度财报。公司报告本季度每股收益为（$0.16），符合分析师一致预期的（$0.16），据 Zacks 报道。公司本季度的收入为 30,000 美元，而分析师预期为 30,000 美元。</p>
</div><h2>InflaRx Price Performance</h2>
<div class="lb-trans"><h2>InflaRx 价格表现</h2>
</div><p>Shares of IFRX traded up $0.03 during mid-day trading on Wednesday, hitting $1.68. The company's stock had a trading volume of 2,327,579 shares, compared to its average volume of 1,075,154. InflaRx has a fifty-two week low of $0.71 and a fifty-two week high of $2.82. The firm has a 50-day moving average price of $1.38 and a 200 day moving average price of $1.18. The stock has a market capitalization of $112.78 million, a price-to-earnings ratio of -2.18 and a beta of 1.38.</p>
<div class="lb-trans"><p>周三午盘交易中，IFRX 股价上涨 0.03 美元，达到 1.68 美元。该公司的股票交易量为 2,327,579 股，而其平均交易量为 1,075,154 股。InflaRx 的 52 周低点为 0.71 美元，52 周高点为 2.82 美元。该公司的 50 日移动平均价格为 1.38 美元，200 日移动平均价格为 1.18 美元。该股票的市值为 1.1278 亿美元，市盈率为-2.18，贝塔值为 1.38。</p>
</div><h2>Institutional Trading of InflaRx</h2>
<div class="lb-trans"><h2>InflaRx 的机构交易</h2>
</div><p>Institutional investors have recently made changes to their positions in the stock. Woodline Partners LP acquired a new stake in InflaRx in the first quarter valued at approximately $766,000. Adage Capital Partners GP L.L.C. bought a new position in InflaRx during the second quarter worth $262,000. Finally, Cubist Systematic Strategies LLC raised its position in shares of InflaRx by 33.9% during the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company's stock valued at $31,000 after buying an additional 7,616 shares during the last quarter. 42.39% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>机构投资者最近对该股票的持仓进行了调整。Woodline Partners LP 在第一季度收购了 InflaRx 的新股份，价值约为 766,000 美元。Adage Capital Partners GP L.L.C.在第二季度购买了 InflaRx 的新头寸，价值为 262,000 美元。最后，Cubist Systematic Strategies LLC 在第一季度将其在 InflaRx 的持仓增加了 33.9%。Cubist Systematic Strategies LLC 目前拥有 30,053 股该公司的股票，价值 31,000 美元，此前在上个季度又购买了 7,616 股。目前，42.39% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>A number of equities research analysts recently weighed in on the stock. HC Wainwright initiated coverage on shares of InflaRx in a report on Tuesday, September 2nd. They set a &#34;buy&#34; rating and a $6.00 price target for the company. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of InflaRx in a report on Wednesday, November 5th. Wall Street Zen lowered InflaRx from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday. Guggenheim lifted their price objective on InflaRx from $10.00 to $22.00 and gave the stock a &#34;buy&#34; rating in a report on Monday. Finally, Raymond James Financial reissued an &#34;outperform&#34; rating on shares of InflaRx in a research report on Tuesday. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $8.60.</p>
<div class="lb-trans"><p>一些股票研究分析师最近对该股票发表了看法。HC Wainwright 在 9 月 2 日的报告中对 InflaRx 的股票进行了覆盖，给予 “买入” 评级，并设定目标价为 6.00 美元。Weiss Ratings 在 11 月 5 日的报告中重新发布了对 InflaRx 的 “卖出（d-）” 评级。华尔街 Zen 在周六的研究报告中将 InflaRx 的评级从 “持有” 下调至 “卖出”。Guggenheim 在周一的报告中将 InflaRx 的目标价从 10.00 美元上调至 22.00 美元，并给予该股票 “买入” 评级。最后，Raymond James Financial 在周二的研究报告中重新发布了对 InflaRx 的 “跑赢大盘” 评级。五位研究分析师对该股票给予了 “买入” 评级，一位分析师给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，平均目标价为 8.60 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on IFRX</strong></p>
<div class="lb-trans"><p><strong>查看我们对 IFRX 的最新股票分析</strong></p>
</div><h2>InflaRx Company Profile</h2>
<div class="lb-trans"><h2>InflaRx 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.</p>
<div class="lb-trans"><p>InflaRx N.V.是一家临床阶段的生物制药公司，在德国和美国发现并开发使用 C5a 技术的抑制剂。该公司的 C5a 是一种炎症介质，参与多种自身免疫和其他炎症性疾病的进展。其主要产品候选药物是 vilobelimab，一种新型的静脉注射首创抗 C5a 单克隆抗体，已完成针对 hidradenitis suppurativa（一种罕见且慢性的致残性全身性炎症皮肤病）的第三阶段临床试验；针对抗中性粒细胞细胞质抗体相关性血管炎（一种罕见且危及生命的自身免疫疾病）的第二阶段临床试验；治疗脓皮病（pyoderma gangraenosum，一种慢性炎症性皮肤疾病）的第二阶段探索性研究；以及治疗对 PD-1/PD-L1 抑制剂耐药/难治的局部晚期或转移性鳞状细胞癌的第二阶段临床开发。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than InflaRx</li>
<li>With Risk Tolerance, One Size Does Not Fit All</li>
<li>Rocket Lab Stock Jumps After Earnings, Despite Neutron Delay</li>
<li>How to Use Stock Screeners to Find Stocks</li>
<li>Occidental Petroleum is a Buy in Q4 2025</li>
<li>Best Energy Stocks - Energy Stocks to Buy Now</li>
<li>3 Beaten-Down Stocks With Rebound Potential This Earnings Season</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票而非 InflaRx</li>
<li>风险承受能力，适合所有人的方案并不存在</li>
<li>Rocket Lab 股票在财报后上涨，尽管 Neutron 延迟</li>
<li>如何使用股票筛选器寻找股票</li>
<li>2025 年第四季度，西方石油是一个买入机会</li>
<li>最佳能源股票 - 现在值得购买的能源股票</li>
<li>3 只被打压的股票在本财报季有反弹潜力</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUZSWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=IFRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in InflaRx Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 InflaRx 吗？</h2>
</div><p>Before you consider InflaRx, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 InflaRx 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InflaRx wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 InflaRx 并不在名单上。</p>
</div><p>While InflaRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 InflaRx 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

InflaRx（纳斯达克代码：IFRX）公布季度财报结果，符合预期